+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Checkpoint Inhibitors"

Ewing Sarcoma - Global Strategic Business Report - Product Thumbnail Image

Ewing Sarcoma - Global Strategic Business Report

  • Report
  • November 2026
  • 377 Pages
  • Global
From
From
Angiosarcoma Treatment - Global Strategic Business Report - Product Thumbnail Image

Angiosarcoma Treatment - Global Strategic Business Report

  • Report
  • November 2026
  • 390 Pages
  • Global
From
From
From
Hyperthermia Cancer Treatment - Global Strategic Business Report - Product Thumbnail Image

Hyperthermia Cancer Treatment - Global Strategic Business Report

  • Report
  • November 2026
  • 384 Pages
  • Global
From
From
Oncolytic Virus Therapy - Global Strategic Business Report - Product Thumbnail Image

Oncolytic Virus Therapy - Global Strategic Business Report

  • Report
  • November 2026
  • 483 Pages
  • Global
From
PARP Inhibitor Biomarkers - Global Strategic Business Report - Product Thumbnail Image

PARP Inhibitor Biomarkers - Global Strategic Business Report

  • Report
  • November 2026
  • 278 Pages
  • Global
From
Stomach Cancer Treatment - Global Strategic Business Report - Product Thumbnail Image

Stomach Cancer Treatment - Global Strategic Business Report

  • Report
  • November 2026
  • 371 Pages
  • Global
From
Epithelioma Treatment - Global Strategic Business Report - Product Thumbnail Image

Epithelioma Treatment - Global Strategic Business Report

  • Report
  • November 2026
  • 380 Pages
  • Global
From
Peptide Drug Conjugates - Global Strategic Business Report - Product Thumbnail Image

Peptide Drug Conjugates - Global Strategic Business Report

  • Report
  • November 2026
  • 282 Pages
  • Global
From
Cancer Biological Therapy - Global Strategic Business Report - Product Thumbnail Image

Cancer Biological Therapy - Global Strategic Business Report

  • Report
  • November 2026
  • 211 Pages
  • Global
From
From
From
Bispecific Antibodies - Global Strategic Business Report 2026 - Product Thumbnail Image

Bispecific Antibodies - Global Strategic Business Report 2026

  • Report
  • November 2026
  • 104 Pages
  • Global
From
Testicular Cancer Drugs - Global Strategic Business Report - Product Thumbnail Image

Testicular Cancer Drugs - Global Strategic Business Report

  • Report
  • November 2026
  • 269 Pages
  • Global
From
Hepatocellular Carcinoma Drugs - Global Strategic Business Report - Product Thumbnail Image

Hepatocellular Carcinoma Drugs - Global Strategic Business Report

  • Report
  • November 2026
  • 198 Pages
  • Global
From
Bone Cancer Treatment - Global Strategic Business Report - Product Thumbnail Image

Bone Cancer Treatment - Global Strategic Business Report

  • Report
  • November 2026
  • 367 Pages
  • Global
From
Oncology Clinical Trials - Global Strategic Business Report - Product Thumbnail Image

Oncology Clinical Trials - Global Strategic Business Report

  • Report
  • November 2026
  • 283 Pages
  • Global
From
Loading Indicator

The Checkpoint Inhibitors market is a subset of the Oncology Drugs market, which focuses on treatments for cancer. Checkpoint Inhibitors are a type of immunotherapy, which works by blocking certain proteins that act as “checkpoints” in the body’s immune system. By blocking these checkpoints, the body’s immune system is able to recognize and attack cancer cells. This type of therapy has been found to be effective in treating a variety of cancers, including melanoma, non-small cell lung cancer, and bladder cancer. The Checkpoint Inhibitors market is highly competitive, with many companies developing and marketing their own products. Some of the major players in the market include Merck, Bristol-Myers Squibb, Roche, AstraZeneca, and Pfizer. Show Less Read more